Across TCGA pan-cancer cohorts, ALG1L Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ALG1L data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALG1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALG1L expression acts as an unfavorable survival marker.

HNSC, ESCA, and UCEC are the cancer types where ALG1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.211	0.713	<.001	24	view →
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ALG1L tumor-vs-normal RNA expression · all ALG1L data types